ci 988 has been researched along with endomorphin 2 in 1 studies
| Studies (ci 988) | Trials (ci 988) | Recent Studies (post-2010) (ci 988) | Studies (endomorphin 2) | Trials (endomorphin 2) | Recent Studies (post-2010) (endomorphin 2) |
|---|---|---|---|---|---|
| 147 | 8 | 14 | 443 | 0 | 112 |
| Protein | Taxonomy | ci 988 (IC50) | endomorphin 2 (IC50) |
|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.0482 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.001 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0241 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamei, J; Nagase, H; Zushida, K | 1 |
1 other study(ies) available for ci 988 and endomorphin 2
| Article | Year |
|---|---|
Role of cholecystokinin in the reduction of endomorphin-2-induced antinociception in diabetic mice.
Topics: Analgesics; Animals; Behavior, Animal; Cholecystokinin; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Indoles; Injections, Intraventricular; Meglumine; Mice; Mice, Inbred ICR; Nociceptors; Oligopeptides; Pain; Pain Measurement; Sincalide | 2001 |